AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17299114 — intervention group
Group type: EXPERIMENTAL
Intervention: Large portion condition
Number of subjects: 75
Study 17299114 — intervention group
Group type: COMPARATOR
Intervention: Reference condition
Number of subjects: 75
Study 17299114 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selection condition
Number of subjects: 75
Study 15339465 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiangdan Injection plus standard treatment for coronary heart disease
Number of subjects: 56
Study 15339465 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for coronary heart disease (Control)
Number of subjects: 56
Study 11996874 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated stress management program (7 sessions of 1 hour over 4 weeks)
Number of subjects: 47
Study 11996874 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated stress management program
Number of subjects: 47
Study 11996874 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation (tape only)
Number of subjects: 47
Study 9817278 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of MCV chemotherapy before concurrent cisplatin and radiation therapy (arm 1, n=61)
Number of subjects: 123
Study 9817278 — intervention group
Group type: COMPARATOR
Intervention: Standard induction therapy (arm 2, n=62)
Number of subjects: 123
Study 7654489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexfenfluramine (d-F) 15.5 mg base infused over 3 h
Number of subjects: 20
Study 7654489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexfenfluramine (d-F) 25.9 mg base in capsules
Number of subjects: 20
Study 7654489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral dexfenfluramine (d-F)
Number of subjects: 20
Study 2668525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 0
Study 2668525 — intervention group
Group type: COMPARATOR
Intervention: Amiloride + Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 671150 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary infant formula (supplemented with iron)
Number of subjects: 132
Study 671150 — intervention group
Group type: COMPARATOR
Intervention: Cow milk formula (no iron supplementation)
Number of subjects: 132
Study 671150 — intervention group
Group type: COMPARATOR
Intervention: Breast feeding (no iron supplementation)
Number of subjects: 132
Study 30864006 — intervention group
Group type: EXPERIMENTAL
Intervention: PPB + IRLA (3.0 mL of 2% lidocaine injected at the bilateral pelvic plexus)
Number of subjects: 163
Study 30864006 — intervention group
Group type: EXPERIMENTAL
Intervention: PNB + IRLA (3.0 mL of 2% lidocaine injected at both periprostatic nerves)
Number of subjects: 163
Study 30864006 — intervention group
Group type: COMPARATOR
Intervention: IRLA alone
Number of subjects: 163
Study 28072681 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-focused cognitive behavioral health education program (GCBHEP) for 10 weeks
Number of subjects: 20
Study 28072681 — intervention group
Group type: COMPARATOR
Intervention: Conventional counseling for 10 weeks
Number of subjects: 20
Study 25847131 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 0.1 mg/kg twice a day on days 1 and 3 or days 2 and 4
Number of subjects: 27
Study 25847131 — intervention group
Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 27
Study 23667063 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m(2)
Number of subjects: 54
Study 23667063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23667063 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 54
Study 21224458 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery graft
Number of subjects: 757
Study 21224458 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein graft
Number of subjects: 757
Study 19473751 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 100
Study 19473751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18034178 — intervention group
Group type: EXPERIMENTAL
Intervention: March of Dimes NICU Family Support (NFS)
Number of subjects: 0
Study 16176939 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA-SC 104 (104 mg/0.65 ml every 3 months)
Number of subjects: 300
Study 16176939 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide (3.75 mg monthly or 11.25 mg every 3 months)
Number of subjects: 300
Study 16176939 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA-SC 104
Number of subjects: 300
Study 16176939 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 300
Study 16176939 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA-SC 104 and Leuprolide
Number of subjects: 300
Study 14639444 — intervention group
Group type: EXPERIMENTAL
Intervention: DJATA1
Number of subjects: 6
Study 14639444 — intervention group
Group type: EXPERIMENTAL
Intervention: DJATA2
Number of subjects: 6
Study 10581822 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathic care
Number of subjects: 33
Study 10581822 — intervention group
Group type: COMPARATOR
Intervention: Standard GP care
Number of subjects: 33
Study 9170576 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy (goserelin acetate depot 3.6 mg subcutaneously every 4 weeks)
Number of subjects: 41
Study 9170576 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy (goserelin acetate depot 3.6 mg subcutaneously and cyclophosphamide 1000 mg/m2 intravenously every 4 weeks)
Number of subjects: 41
Study 9170576 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy
Number of subjects: 41
Study 1951075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sotalol (40 mg every 6 hours for 6 days)
Number of subjects: 300
Study 1951075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 1951075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sotalol
Number of subjects: 300
Study 7230984 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antimicrobial bowel preparation with metronidazole and kanamycin
Number of subjects: 72
Study 7230984 — intervention group
Group type: COMPARATOR
Intervention: Parenteral antibiotic prophylaxis with metronidazole and kanamycin
Number of subjects: 72
Study 31919035 — intervention group
Group type: EXPERIMENTAL
Intervention: Small sided games (SSG)
Number of subjects: 14
Study 31919035 — intervention group
Group type: EXPERIMENTAL
Intervention: Large sided games (LSG)
Number of subjects: 14
Study 31919035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-goal games (MG)
Number of subjects: 14
Study 31919035 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit training (CT)
Number of subjects: 14
Study 31919035 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendly matches (FM)
Number of subjects: 14
Study 30047802 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week programme plus 6 physical activity counselling sessions
Number of subjects: 36
Study 30047802 — intervention group
Group type: COMPARATOR
Intervention: 12-week programme comprising an orientation and access to fitness centre resources
Number of subjects: 36
Study 30047802 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity counselling
Number of subjects: 36
Study 30047802 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases from baseline in IPAQ moderate/vigorous activity minutes
Number of subjects: 36
Study 29306228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TnX‐A)
Number of subjects: 54
Study 29306228 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (Des)
Number of subjects: 54
Study 29306228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 29306228 — intervention group
Group type: EXPERIMENTAL
Intervention: TnX‐A + Des
Number of subjects: 54
Study 25875795 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-step treatment
Number of subjects: 47
Study 25875795 — intervention group
Group type: COMPARATOR
Intervention: 2-step treatment
Number of subjects: 47
Study 23571173 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose inactivated hepatitis A vaccine (Healive(®))
Number of subjects: 5
Study 23571173 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose inactivated hepatitis A vaccine (Healive(®))
Number of subjects: 5
Study 23571173 — intervention group
Group type: COMPARATOR
Intervention: Attenuated vaccine B
Number of subjects: 5
Study 23571173 — intervention group
Group type: COMPARATOR
Intervention: Attenuated vaccine C
Number of subjects: 5
Study 23571173 — intervention group
Group type: COMPARATOR
Intervention: Attenuated vaccine A
Number of subjects: 5
Study 21819749 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of i.v. dexamethasone preoperatively and again after 24 and 48 hours after surgery
Number of subjects: 74
Study 21819749 — intervention group
Group type: EXPERIMENTAL
Intervention: Three pseudoephedrine tablets (60 mg) per day for 1 week
Number of subjects: 74
Study 21819749 — intervention group
Group type: EXPERIMENTAL
Intervention: Three pseudoephedrine tablets (60 mg) per day for 2 weeks
Number of subjects: 74
Study 20068365 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon 0.5 million IU b.i.d., thalidomide (100 mg b.i.d. reduced to 100 mg daily), or celecoxib (400 mg daily reduced to 200 mg)
Number of subjects: 62
Study 20068365 — intervention group
Group type: EXPERIMENTAL
Intervention: two-drug combinations of alpha-interferon, thalidomide or celecoxib
Number of subjects: 62
Study 20068365 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 62
Study 17565807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin and gentamicin for 7 days, starting between 24 and 36 hours of life
Number of subjects: 144
Study 17565807 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 144
Study 17565807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin and gentamicin
Number of subjects: 144
Study 15507074 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty index based on comprehensive geriatric assessment (FI-CGA)
Number of subjects: 169
Study 15507074 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 169
Study 11281338 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg and verapamil 180 mg
Number of subjects: 0
Study 11281338 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg and amlodipine 5 mg
Number of subjects: 0
Study 11281338 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril 2 mg
Number of subjects: 0
Study 9400948 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11 (irinotecan) and VP‐16 (etoposide) given sequentially in Arm A: CPT‐11 over 90 min on days 1-3, VP‐16 over 60 min on days 4-6
Number of subjects: 27
Study 9400948 — intervention group
Group type: EXPERIMENTAL
Intervention: VP‐16 (etoposide) and CPT‐11 (irinotecan) given sequentially in Arm B: VP‐16 on days 1-3, CPT‐11 on days 4-6
Number of subjects: 27
Study 9400948 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF given daily on days 7-17 to all patients
Number of subjects: 27
Study 7955195 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary artery (IMA) grafts
Number of subjects: 912
Study 7955195 — intervention group
Group type: EXPERIMENTAL
Intervention: IMA plus vein grafts
Number of subjects: 912
Study 7955195 — intervention group
Group type: COMPARATOR
Intervention: Vein grafts
Number of subjects: 912
Study 7955195 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical events in group 1 (IMA and vein grafts)
Number of subjects: 912
Study 7955195 — intervention group
Group type: COMPARATOR
Intervention: Clinical events in group 2 (only vein grafts)
Number of subjects: 912
Study 3622189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern-recognition program
Number of subjects: 0
Study 3622189 — intervention group
Group type: COMPARATOR
Intervention: Human scorers
Number of subjects: 0
Study 31427901 — intervention group
Group type: EXPERIMENTAL
Intervention: HG-Herbst
Number of subjects: 26
Study 31427901 — intervention group
Group type: COMPARATOR
Intervention: HG-TB
Number of subjects: 26
Study 28544917 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 0.5g/kg and Furosemide 0.5mg/kg
Number of subjects: 51
Study 28544917 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 1g/kg and Furosemide 0.5mg/kg
Number of subjects: 51
Study 28544917 — intervention group
Group type: COMPARATOR
Intervention: Mannitol 0.5g/kg and Placebo
Number of subjects: 51
Study 28544917 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (0.5g/kg or 1g/kg) with Furosemide (0.5mg/kg)
Number of subjects: 51
Study 24931756 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral Dipeptiven(®) supplementation of 0.5 g/kg/day
Number of subjects: 82
Study 24931756 — intervention group
Group type: COMPARATOR
Intervention: Standard isocaloric isoproteinic nutritional support
Number of subjects: 82
Study 23609487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy‐based self‐help program delivered by the Internet with e‐mail guidance
Number of subjects: 29
Study 23609487 — intervention group
Group type: COMPARATOR
Intervention: Bibliotherapy with e‐mail guidance
Number of subjects: 29
Study 23609487 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Internet and bibliotherapy)
Number of subjects: 29
Study 21902998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpectomy with smear layer removal (Group 1)
Number of subjects: 18
Study 21902998 — intervention group
Group type: COMPARATOR
Intervention: Pulpectomy without smear layer removal (Group 2)
Number of subjects: 18
Study 19176222 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-focused therapy (SFT) combined with treatment-as-usual (TAU)
Number of subjects: 32
Study 19176222 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) alone
Number of subjects: 32
Study 17076982 — intervention group
Group type: EXPERIMENTAL
Intervention: IM aripiprazole 9.75 mg
Number of subjects: 325
Study 17076982 — intervention group
Group type: EXPERIMENTAL
Intervention: IM haloperidol 6.5 mg
Number of subjects: 325
Study 17076982 — intervention group
Group type: COMPARATOR
Intervention: IM placebo
Number of subjects: 325
Study 17076982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aripiprazole
Number of subjects: 325
Study 17076982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral haloperidol
Number of subjects: 325
Study 17076982 — intervention group
Group type: EXPERIMENTAL
Intervention: IM aripiprazole
Number of subjects: 325
Study 17076982 — intervention group
Group type: EXPERIMENTAL
Intervention: IM haloperidol
Number of subjects: 325
Study 15474895 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg p.o. QD)
Number of subjects: 22
Study 15474895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12126875 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg administered orally
Number of subjects: 14
Study 12126875 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study 9576366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal calcitriol (5.4 ± 1.2 microg/week, maximum 6.6 ± 1.5 microg/week) administered twice per week before bedtime.
Number of subjects: 8
Study 9576366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal calcitriol
Number of subjects: 8
Study 7539187 — intervention group
Group type: EXPERIMENTAL
Intervention: UroLume Endourethral Prosthesis
Number of subjects: 0
Study 7539187 — intervention group
Group type: EXPERIMENTAL
Intervention: thermosensitive and biodegradable prostheses
Number of subjects: 0
Study 2651014 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mg ergoloid mesylates per day
Number of subjects: 97
Study 144507 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg D-penicillamine (DP)
Number of subjects: 179
Study 144507 — intervention group
Group type: COMPARATOR
Intervention: 5 mg D-penicillamine (DP)
Number of subjects: 179
Study 31422458 — intervention group
Group type: EXPERIMENTAL
Intervention: IV PCA oxycodone
Number of subjects: 270
Study 31422458 — intervention group
Group type: COMPARATOR
Intervention: Oral oxycodone
Number of subjects: 270
Study 26882121 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5*3/*3 and NR1I2 T/T mutations
Number of subjects: 42
Study 26882121 — intervention group
Group type: COMPARATOR
Intervention: Wild-type subjects
Number of subjects: 42
Study 25432952 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 µg peginterferon beta‐1a every 2 weeks
Number of subjects: 0
Study 25432952 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 µg peginterferon beta‐1a every 4 weeks
Number of subjects: 0
Study 25432952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initially assigned)
Number of subjects: 0
Study 23245590 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin (45mg/m²/day) for 12 weeks
Number of subjects: 57
Study 23245590 — intervention group
Group type: COMPARATOR
Intervention: Peg-interferon and ribavirin alone
Number of subjects: 57
Study 21288774 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor and switch to second-line at 1000 copies per mL (PI-low)
Number of subjects: 266
Study 21288774 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor and switch at 30,000 copies per mL (PI-higher)
Number of subjects: 266
Study 21288774 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI and switch at 1000 copies per mL (NNRTI-low)
Number of subjects: 266
Study 21288774 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI and switch at 30,000 copies per mL (NNRTI-higher)
Number of subjects: 266
Study 21288774 — intervention group
Group type: COMPARATOR
Intervention: Switching at low threshold (1000 copies per mL)
Number of subjects: 266
Study 21288774 — intervention group
Group type: COMPARATOR
Intervention: Switching at higher threshold (30,000 copies per mL)
Number of subjects: 266
Study 21288774 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-higher group
Number of subjects: 266
Study 21288774 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment strategies
Number of subjects: 266
Study 21288774 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor resistance
Number of subjects: 266
Study 21288774 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC stage-C events and grade 3/4 adverse events
Number of subjects: 266
Study 19480232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Splint (MAS)
Number of subjects: 27
Study 19480232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue Stabilizing Device (TSD)
Number of subjects: 27
Study 16081106 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ plus FEWP
Number of subjects: 235
Study 16081106 — intervention group
Group type: COMPARATOR
Intervention: CBZ monotherapy
Number of subjects: 235
Study 16081106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 15143081 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF + EPO
Number of subjects: 38
Study 15143081 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 38
Study 10831021 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg, administered orally)
Number of subjects: 16
Study 10831021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8922889 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose aprotinin during surgery
Number of subjects: 40
Study 8922889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1348773 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-set dialysate delivery system
Number of subjects: 40
Study 1348773 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate delivery system
Number of subjects: 40
Study 3910160 — intervention group
Group type: EXPERIMENTAL
Intervention: Stump invagination
Number of subjects: 735
Study 3910160 — intervention group
Group type: COMPARATOR
Intervention: Simple ligation
Number of subjects: 735
Study 31862436 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month personalized, remotely delivered survivorship care plan (SCP) intervention
Number of subjects: 342
Study 31862436 — intervention group
Group type: EXPERIMENTAL
Intervention: $50 upfront incentive
Number of subjects: 342
Study 31862436 — intervention group
Group type: COMPARATOR
Intervention: $25 upfront incentive
Number of subjects: 342
Study 31862436 — intervention group
Group type: COMPARATOR
Intervention: Different recruitment strategies (shorter approach packets and tiered consent)
Number of subjects: 342
Study 31752872 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS) for family planning education and support
Number of subjects: 0
Study 28330629 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle
Number of subjects: 500
Study 28330629 — intervention group
Group type: COMPARATOR
Intervention: Cannula over needle
Number of subjects: 500
Study 26100026 — intervention group
Group type: EXPERIMENTAL
Intervention: HEADS‐UP intervention (structured, multidisciplinary team briefing)
Number of subjects: 7840
Study 26100026 — intervention group
Group type: EXPERIMENTAL
Intervention: HEADS‐UP intervention
Number of subjects: 7840
Study 23941053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) programme
Number of subjects: 288
Study 23941053 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard university courses)
Number of subjects: 288
Study 21957940 — intervention group
Group type: EXPERIMENTAL
Intervention: Encircling constriction of the superficial femoral vein with colour Doppler monitoring
Number of subjects: 87
Study 21957940 — intervention group
Group type: COMPARATOR
Intervention: Encircling constriction of the superficial femoral vein without colour Doppler monitoring
Number of subjects: 87
Study 19828031 — intervention group
Group type: EXPERIMENTAL
Intervention: CPI>0
Number of subjects: 877
Study 19828031 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one tooth lost
Number of subjects: 877
Study 19828031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth loss in molars
Number of subjects: 877
Study 19828031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth loss in molar-and anterior regions
Number of subjects: 877
Study 19828031 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting periodontal problems (bad breath)
Number of subjects: 877